– USA, NY – Avenue Therapeutics, Inc. (NASDAQ: ATXI), a specialty pharmaceutical company focused on the development and commercialization of intravenous tramadol, today announced that Dr. Thomas G. Moore has been appointed to its Board of Directors.
“Tom’s breadth and depth of operational and commercial experience, which includes leadership in the acute care pharmaceutical business, will be a significant asset to Avenue,” said Dr. Lindsay Rosenwald, Avenue’s Executive Chairman. “Tom is well suited to help Avenue execute on its mission of bringing IV tramadol to the U.S. market, and we are excited to add him to our Board.”
About Dr Thomas Moore
Thomas G. Moore is a retired pharmaceutical industry executive with more than 35 years of strategic and operational experience including extensive knowledge of the acute care pharmaceutical business, strategic planning and business development based on his work at major public companies. Dr. Moore served as President of Hospira USA from 2009 until his retirement in 2014. He was President of Global Pharmaceuticals for Hospira Worldwide, Inc. from 2007 to 2009, and served as Vice President and General Manager of Specialty Pharmaceuticals for Hospira, Inc. from 2003 to 2007. Dr. Moore sits on the Board of Directors of Akorn Pharmaceuticals and the Board of Trustees for Rosalind Franklin University of Medicine and Science.
“Avenue is nearing Phase 3 completion for IV tramadol, which could become an important addition in acute pain management in the U.S.,” said Dr. Moore. “I am delighted to lend my expertise to the organization and join the Board of Directors to help unlock value from this program.”
Dr. Moore received his undergraduate degree from Loyola Marymount University, Los Angeles, and his Doctor of Pharmacy from the University of Southern California.
About Avenue Therapeutics
Avenue is a specialty pharmaceutical company focused on the development and commercialization of intravenous tramadol for the management of moderate to moderately severe postoperative pain. IV tramadol may fill a gap in the acute pain market between IV acetaminophen/NSAIDs and IV conventional narcotics. Avenue is currently evaluating IV tramadol in a pivotal Phase 3 program for the management of postoperative pain. Avenue is headquartered in New York City and was founded by Fortress Biotech, Inc. (NASDAQ:FBIO).
For more information : https://www.avenuetx.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.